Feature
Lorcaserin shows CV safety in CAMELLIA-TIMI 61
Lorcaserin is the first weight-loss drug proven to have cardiovascular safety, says Dr. Erin A. Bohula.
August 26, 2018
We have updated our Privacy Policy. Please take the time to review
Practice Management
September 19, 2018
Senators unveil legislation to protect patients against surprise medical bills
September 19, 2018
Endoscopy
August 14, 2018
AGA Clinical Practice Update: Tumor seeding with endoscopic procedures
August 14, 2018
August 1, 2018
Endoscopic screening tied to significantly lower risk of death from gastric cancer
August 1, 2018
July 16, 2018
Newer cholangioscopy system safe and effective for difficult biliary stones
July 16, 2018
Liver Disease
September 12, 2018
Outpatient costs soar for Medicare patients with chronic hepatitis B
September 12, 2018
September 2, 2018
A postgraduate tour through the biliary tree, pancreas, and liver
September 2, 2018
August 30, 2018
Avatrombopag cut procedure-related transfusions in patients with thrombocytopenia, chronic liver disease
August 30, 2018
Video Library
July 12, 2018
Machine learning software boosts colonoscopists’ adenoma detection rates
July 12, 2018
June 6, 2018
Web portal does not reduce phone encounters or office visits for IBD patients
June 6, 2018
Commentary
Question 1 of 5
News From the AGA
-
-
AGA funds noteworthy microbiome research -
Strides in digestive cancer research: Two research projects to note -
Registration now open for the Crohn’s & Colitis Congress -
-
AGA continues to ‘push the envelope,’ President says -
-
Don’t lose your access to essential resources -
A successful career starts with taking charge -
AGA honors GI Congressional champions Sen. Bill Cassidy and Rep. Mike Thompson
From the AGA Journals
-
-
-
-
Study examines POEM learning curve -
-
AGA Clinical Practice Update: Tumor seeding with endoscopic procedures -
Endoscopic screening tied to significantly lower risk of death from gastric cancer -
Fine-needle aspirate, biopsy found equivalent in randomized trial -
Who are the 'high-need, high-cost' patients? -
